Inflammatory bowel disease (IBD) is an autoimmune disorder of the gastrointestinal tract with complex pathogenesis, and current animal models relying on endogenous immune activation have limited translational relevance for evaluating human biologics. GemPharmatech has established a humanized IBD model combining human immune system reconstitution (huHSC-NCG-M/hIL15) with dextran sulfate sodium (DSS) challenge to better reflect human disease. This model exhibits human T cell and myeloid cell reconstitution and DSS-induced colitis features, including weight loss, shortened colon length, reduced survival, and epithelial damage. It also responds to adalimumab treatment, supporting its utility for translational IBD research and therapeutic evaluation.